logo
logo

Affinia Therapeutics secured $40 million in Series C financing, led by New Enterprise Associates, to advance AFTX-201 for BAG3 dilated cardiomyopathy.

Oct 07, 2025•3 days ago

Amount Raised

$40 Million

Round Type

series c

WalthamBiotechnologyHealth Care

Investors

Perceptive AdvisorsMass General Brigham VenturesGv (Formerly Google Ventures)F PrimeAvidity PartnersAtlas VentureAlexandria Venture Investments, LlcEli Lilly & CompanyNew Enterprise Associates

Description

Affinia Therapeutics has closed a $40 million Series C financing led by New Enterprise Associates, with participation from Eli Lilly & Company and other existing investors. The funds will support IND submission and clinical activities for AFTX-201, targeting BAG3 dilated cardiomyopathy. Affinia aims to submit an Investigational New Drug application by Q4 2025 and start a Phase 1/2 trial in Q1 2026. The financing also enables further development within Affinia's gene therapy pipeline.

Company Information

Company

Affinia Therapeutics

Location

Waltham, Massachusetts, United States

About

Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ pipeline of first-in-class or best-in-class product candidates in cardiovascular and neurological diseases leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech